Skip to content

Trial Summary

An Open-Label, Signal Generating, Phase 2 Study Of Her-Vaxx In Combination With Chemotherapy Or Pembrolizumab In Patients With Metastatic Her2/Neu Over-Expressing Gastric Or Gastroesophageal Junction (Gej) Adenocarcinomas Who Have Previously Received Trastuzumab And Progressed On This Treatment

Acronym:

nextHERIZON

ACTRN/NCT /ethics:

NCT05311176

Scientific title:

A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)

Sponsor / Cooperative group:

Imugene Limited

Trial & Patient Characteristics

Cancer TypeStomach & Oesophageal
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2022-05-17
Anticipated End Date2025-11-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Emailstella.papacharissiou@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Timothy Price
Recruitment StatusNot Yet Recruiting